Sign inJoin waitlistJoin the waitlist

Huda Salman

Program Leader - Leukemia · Indiana University School of Medicine

Credentials: · · · · · · · · ·

History

Indiana University School of Medicine
Present

Research

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Leukemia · 2017 · 158 citations
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024 · 118 citations
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Oncotarget · 2016 · 103 citations

YM
Yupo Ma
8 papers
Alexander Jares
3 papers
Fengshuo Lan
3 papers
Jessica Petrov
3 papers
Lulu Yan
3 papers
Tahmeena Ahmed
3 papers
AT
Alan Tan
2 papers · 2 as a resident
Daniel DeAngelo
2 papers
Farrukh Awan
2 papers
Heiko Konig
2 papers
Joseph Sparano
2 papers
LS
Lisa Senzel
2 papers

Grants

CD4 Redirected Chimeric Antigen Receptor T Cell Therapy for CD4 Positive T Cell Neoplasms
Food and Drug Administration · R01
Contact PI · $3.1M · Indiana University Indianapolis
2020–2027

Clinical trials

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Principal investigator · Recruiting · Phase 1
Huda Salman
2024–2042
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Principal investigator · Recruiting · Phase 1
Huda Salman
2024–2043
CD4CAR for CD4+ Leukemia and Lymphoma
Principal investigator · Recruiting · Phase 1
Huda Salman
2020–2042